Table 1.
Characteristics of the included studies
|
Ref.
|
Year
|
Country
|
Sample
|
Separation Solution
|
Markers and expression level on PC CTC
|
Cases
|
No-positive
|
Treatment
|
Outcome
|
Follow-up time
|
| Xing et al[14] | 2021 | China | Peripheral blood | SE-iFISH | CD44+ CTEC: DAPI +/CD45-/CD31 +/CD44 +/Vimentin (+ or -) with aneuploid CEP8 | 73 | Not reported | Surgery | OS/DFS | Median 10.8 mo (1.2-31.8 mo) |
| Semaan et al[15] | 2021 | United States | Peripheral blood | DEP-FFF | pEMT-CTC: CD45 -, EpCAM + and/or Pan-CK +, Vimentin +, DAPI + | 31 early stages (74 total) | 28 | Surgery/neoadjuvant treatment | OS/PFS | Median 15.4 mo (0-43.1 mo) |
| Padillo-Ruiz et al[21] | 2021 | Spain | Central venous catheter and portalblood | ICC | DAPI +/CK +/CD45 - | 35 | 35 | Surgery/chemotherapy | OS/DFS | 24 mo |
| Court et al[16] | 2018 | United States | Peripheral blood | NanoVelcro chip | DAPI +/CD45 -/CK +; CD45 positivity greater than 2 × background | 40 early stages (126 total) | 27 | Surgery/chemotherapy | OS/RFS | ≥ 24 mo |
| Cheng et al[17] | 2022 | China | Peripheral blood | LT-PCR | FR + CTC | 25 early stages (44 total) | 13 | Surgery/chemotherapy | OS/DFS | Median 20 mo (6-28 mo) |
| White et al[18] | 2021 | United States | Peripheral blood and portal venous blood | CellSearch | DAPI +/CK + /CD45 - | 33 early stages (34 total) | 21 | Surgery/neoadjuvant treatment | OS/RFS | Median 14.1 mo (0.86-1.97 mo) |
| Bissolati et al[19] | 2014 | Italy | Peripheral blood and portal venous blood | CellSearch | DAPI +/CK +/CD45 - | 20 | 9 | Surgery/chemotherapy | OS/PFS | Median 39.2 mo (36-45 mo) |
| Hugenschmidt et al[20] | 2021 | Norway | Peripheral blood | CellSearch | EpCAM +/DAPI +/CK +/CD45 - | 98 | 7 | Surgery | CSS/DFS | Median 96 mo (63-126 mo) |
DEP-FFF: Dielectrophoresis-field flow fractionation; ICC: Immunocytochemistry; SE-iFISH: Subtraction enrichment and immunostaining-fluorescence in situ hybridization; PC: Pancreatic cacner ; CTCs: Circulating tumor cells; LT-PCR: Ligand-targeted polymerase chain reaction; CK: Cytokeratin; DAPI: 4',6-diamidino-2-phenylindole; EpCAM: Epithelial cell adhesion molecule; CSS: Cancer specific survival; DFS: Disease-free survival; OS: Overall survival; PFS: Progression-free survival; pEMT: Partial epithelial-mesenchymal transition.